Form 4: West Pharma VP Converts RSUs, Adjusts Holdings

West Pharmaceutical Services VP & Treasurer Charles Witherspoon converted restricted stock units into common stock and subsequently disposed of shares for tax obligations.

Summary

• Charles Witherspoon, VP & Treasurer of West Pharmaceutical Services Inc. (WST), reported transactions involving the company's common stock.
• On February 20, 2026, Witherspoon acquired 60.22 shares of common stock upon the conversion of restricted stock units (RSUs).
• Following this acquisition, beneficial ownership of common stock increased to 1,429.966 shares.
• Concurrently, 22.069 shares of common stock were disposed of at a price of $241.12 per share to cover tax withholding obligations related to the RSU vesting.
• After the disposition, Witherspoon's direct beneficial ownership of common stock stands at 1,407.897 shares.
• The derivative security table indicates that 60.22 restricted stock units were converted, leaving 177.644 RSUs beneficially owned.
• The original grant of 237 restricted stock units occurred on February 18, 2025, vesting in four equal annual installments on February 20th each year.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event. The transactions are routine for executive compensation and do not provide new insights into the company's operational or financial performance.

Positives

• The vesting and conversion of restricted stock units represent a realization of compensation for the reporting person, indicating continued alignment of management's interests with shareholders.

Negatives

• The disposition of 22.069 shares of common stock for tax withholding purposes reduces the reporting person's direct ownership, though this is a standard practice following RSU vesting.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider transactions, such as RSU conversions and tax-related sales, are common across industries and typically do not signal significant shifts in broader industry trends or competitive landscapes.

Next Steps

• Future annual vesting of the remaining restricted stock units on February 20th each year.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of restricted stock units and a subsequent sale for tax purposes. It does not contain any new material information regarding the company's financial performance, strategic direction, or operational outlook that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as existing investment theses remain unchanged based on this filing.

Keywords

West Pharmaceutical Services, WST, Insider Trading, Form 4, Restricted Stock Units, RSU Conversion, Executive Compensation, Stock Transaction